Compare Cassava Sciences Inc (FLNA) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs M&T Bank Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while M&T Bank Corporation trades at $217.49 (market cap $31.42B). The key difference: M&T Bank Corporation is far larger — about 797.5× Cassava Sciences Inc's market cap, and M&T Bank Corporation pays a 2.76% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and M&T Bank Corporation for 100 Days on average.
| FLNA | MTB | |
|---|---|---|
Market Cap | $39.40M | $31.42B |
Volume | 759,018 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $4.64 | $254.09 |
52-Week Low | $0.68 | $178.63 |
Typical Hold Time | 37 Days | 100 Days |
Enterprise Value | -$43.28M | $47.77B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
MTB trades at $217.49, up 0.41% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 11.52, net income margin of 30.85%, and three consecutive quarterly EPS beats. Recent news highlights loan growth, AI investments, and a new branch opening, while the company maintains a consistent dividend.
The outlook is mixed; analyst consensus is a Buy with a $258.92 price target, but technicals suggest near-term pressure. Key opportunities include earnings momentum and dividend stability, while risks involve cash flow volatility and high debt levels. The stock offers value but requires monitoring of upcoming Q3 2026 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
